PMC:7558233 / 25253-26373 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"631","span":{"begin":384,"end":388},"obj":"Gene"},{"id":"632","span":{"begin":669,"end":673},"obj":"Gene"},{"id":"633","span":{"begin":723,"end":741},"obj":"Gene"},{"id":"634","span":{"begin":775,"end":783},"obj":"Species"},{"id":"635","span":{"begin":916,"end":924},"obj":"Species"},{"id":"636","span":{"begin":125,"end":133},"obj":"Disease"},{"id":"637","span":{"begin":792,"end":803},"obj":"Disease"}],"attributes":[{"id":"A631","pred":"tao:has_database_id","subj":"631","obj":"Gene:3569"},{"id":"A632","pred":"tao:has_database_id","subj":"632","obj":"Gene:3569"},{"id":"A633","pred":"tao:has_database_id","subj":"633","obj":"Gene:1401"},{"id":"A634","pred":"tao:has_database_id","subj":"634","obj":"Tax:9606"},{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"Tax:9606"},{"id":"A636","pred":"tao:has_database_id","subj":"636","obj":"MESH:C000657245"},{"id":"A637","pred":"tao:has_database_id","subj":"637","obj":"MESH:D008231"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Dynamic changes in hematologic and immunologic biomarkers might also be valuable for informing clinicians of the severity of COVID-19 and enabling them to postulate the most probable clinical outcomes [77]. Peripheral blood lymphocyte, eosinophil, and platelet counts could serve as predictors for disease recovery. Progressive increases in the numbers of neutrophils, basophils, and IL-6 levels have been found to be associated with a fatal outcome [18]. Regardless of the disease severity during the initial clinical visit, the absolute lymphocyte count remained substantially lower in non-survivors than in survivors. In addition, higher levels of neutrophil count, IL-6, pro-calcitonin, D-dimer, amyloid A protein, and C-reactive protein have been identified in deceased patients. Marked lymphopenia has also been associated with a fatal outcome; the platelet count was found to be significantly lower in severe patients and even lower in non-survivors. These findings provide a scientific basis for implementing therapeutic interventions targeted at restoring the inflammatory cell count and inflammatory mediators."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T49","span":{"begin":792,"end":803},"obj":"Phenotype"}],"attributes":[{"id":"A49","pred":"hp_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"Dynamic changes in hematologic and immunologic biomarkers might also be valuable for informing clinicians of the severity of COVID-19 and enabling them to postulate the most probable clinical outcomes [77]. Peripheral blood lymphocyte, eosinophil, and platelet counts could serve as predictors for disease recovery. Progressive increases in the numbers of neutrophils, basophils, and IL-6 levels have been found to be associated with a fatal outcome [18]. Regardless of the disease severity during the initial clinical visit, the absolute lymphocyte count remained substantially lower in non-survivors than in survivors. In addition, higher levels of neutrophil count, IL-6, pro-calcitonin, D-dimer, amyloid A protein, and C-reactive protein have been identified in deceased patients. Marked lymphopenia has also been associated with a fatal outcome; the platelet count was found to be significantly lower in severe patients and even lower in non-survivors. These findings provide a scientific basis for implementing therapeutic interventions targeted at restoring the inflammatory cell count and inflammatory mediators."}

{"project":"LitCovid-sentences","denotations":[{"id":"T144","span":{"begin":0,"end":206},"obj":"Sentence"},{"id":"T145","span":{"begin":207,"end":315},"obj":"Sentence"},{"id":"T146","span":{"begin":316,"end":455},"obj":"Sentence"},{"id":"T147","span":{"begin":456,"end":620},"obj":"Sentence"},{"id":"T148","span":{"begin":621,"end":784},"obj":"Sentence"},{"id":"T149","span":{"begin":785,"end":957},"obj":"Sentence"},{"id":"T150","span":{"begin":958,"end":1120},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Dynamic changes in hematologic and immunologic biomarkers might also be valuable for informing clinicians of the severity of COVID-19 and enabling them to postulate the most probable clinical outcomes [77]. Peripheral blood lymphocyte, eosinophil, and platelet counts could serve as predictors for disease recovery. Progressive increases in the numbers of neutrophils, basophils, and IL-6 levels have been found to be associated with a fatal outcome [18]. Regardless of the disease severity during the initial clinical visit, the absolute lymphocyte count remained substantially lower in non-survivors than in survivors. In addition, higher levels of neutrophil count, IL-6, pro-calcitonin, D-dimer, amyloid A protein, and C-reactive protein have been identified in deceased patients. Marked lymphopenia has also been associated with a fatal outcome; the platelet count was found to be significantly lower in severe patients and even lower in non-survivors. These findings provide a scientific basis for implementing therapeutic interventions targeted at restoring the inflammatory cell count and inflammatory mediators."}

{"project":"MyTest","denotations":[{"id":"33078078-32357808-28132405","span":{"begin":202,"end":204},"obj":"32357808"},{"id":"33078078-32407836-28132406","span":{"begin":451,"end":453},"obj":"32407836"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Dynamic changes in hematologic and immunologic biomarkers might also be valuable for informing clinicians of the severity of COVID-19 and enabling them to postulate the most probable clinical outcomes [77]. Peripheral blood lymphocyte, eosinophil, and platelet counts could serve as predictors for disease recovery. Progressive increases in the numbers of neutrophils, basophils, and IL-6 levels have been found to be associated with a fatal outcome [18]. Regardless of the disease severity during the initial clinical visit, the absolute lymphocyte count remained substantially lower in non-survivors than in survivors. In addition, higher levels of neutrophil count, IL-6, pro-calcitonin, D-dimer, amyloid A protein, and C-reactive protein have been identified in deceased patients. Marked lymphopenia has also been associated with a fatal outcome; the platelet count was found to be significantly lower in severe patients and even lower in non-survivors. These findings provide a scientific basis for implementing therapeutic interventions targeted at restoring the inflammatory cell count and inflammatory mediators."}

{"project":"2_test","denotations":[{"id":"33078078-32357808-28132405","span":{"begin":202,"end":204},"obj":"32357808"},{"id":"33078078-32407836-28132406","span":{"begin":451,"end":453},"obj":"32407836"}],"text":"Dynamic changes in hematologic and immunologic biomarkers might also be valuable for informing clinicians of the severity of COVID-19 and enabling them to postulate the most probable clinical outcomes [77]. Peripheral blood lymphocyte, eosinophil, and platelet counts could serve as predictors for disease recovery. Progressive increases in the numbers of neutrophils, basophils, and IL-6 levels have been found to be associated with a fatal outcome [18]. Regardless of the disease severity during the initial clinical visit, the absolute lymphocyte count remained substantially lower in non-survivors than in survivors. In addition, higher levels of neutrophil count, IL-6, pro-calcitonin, D-dimer, amyloid A protein, and C-reactive protein have been identified in deceased patients. Marked lymphopenia has also been associated with a fatal outcome; the platelet count was found to be significantly lower in severe patients and even lower in non-survivors. These findings provide a scientific basis for implementing therapeutic interventions targeted at restoring the inflammatory cell count and inflammatory mediators."}